Del Baldo Giada, Abbas Rachid, De Ioris Maria Antonietta, Di Ruscio Valentina, Alessi Iside, Miele Evelina, Mastronuzzi Angela, Milano Giuseppe Maria
Department of Pediatric Hematology/Oncology, Bambino Gesù Children's Hospital, IRCCS, Piazza di Sant'Onofrio 4, 00165 Rome, Italy.
Centre de Recherche en Epidémiologie et Santé des Populations, INSERM, Université Paris-Sud, 94800 Villejuif, France.
Cancers (Basel). 2022 Jun 22;14(13):3064. doi: 10.3390/cancers14133064.
Ewing sarcoma (ES) is a rare and aggressive pediatric cancer. Numerous studies have attempted to identify new prognostic biomarkers. The predictive value of serum LDH and CRP has not been clearly described, to date.
The objective of our retrospective study was to investigate the prognostic value of LDH and CRP levels and their association with overall survival in a series of ES patients.
Between 2004 and 2019, 89 ES patients were included. In a univariable analysis, high levels of LDH and CRP were associated with the worst prognosis. In a multivariable analysis, only higher LDH values remained associated with a lower survival. The high-LDH-level group experienced all 21 deaths registered in our population (24%) and about 90% of disease progressions. The 5-year overall survival was 66.4% in the high-LDH-level group, while no deaths were observed in the low-LDH-level group. The 5-year progression-free survival was 57.9% in the high-LDH-level group versus 80.4% in the low-LDH-level group.
In our study, LDH levels at diagnosis were strongly correlated with the prognosis, and they might be considered a prognostic factor in Ewing sarcoma. The LDH value, along with its very low cost and its reproducibility in almost all centers, make it suitable as a potential prognostic biomarker in clinical practice.
尤因肉瘤（ES）是一种罕见且侵袭性强的儿童癌症。众多研究试图识别新的预后生物标志物。迄今为止，血清乳酸脱氢酶（LDH）和C反应蛋白（CRP）的预测价值尚未得到明确描述。
我们这项回顾性研究的目的是探讨LDH和CRP水平在一系列ES患者中的预后价值及其与总生存期的关联。
2004年至2019年期间，纳入了89例ES患者。单变量分析中，LDH和CRP水平升高与最差预后相关。多变量分析中，只有较高的LDH值仍与较低生存率相关。高LDH水平组经历了我们研究人群中登记的所有21例死亡（24%）以及约90%的疾病进展。高LDH水平组的5年总生存率为66.4%，而低LDH水平组未观察到死亡病例。高LDH水平组的5年无进展生存率为57.9%，而低LDH水平组为80.4%。
在我们的研究中，诊断时的LDH水平与预后密切相关，可以认为它是尤因肉瘤的一个预后因素。LDH值及其极低的成本以及在几乎所有中心的可重复性，使其适合作为临床实践中潜在的预后生物标志物。
